Division of Shire PLC
Latest From Movetis NV
The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.
Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).
Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions in ophthalmology, an area in which he has specialized. However, with many recent acquisitions yet to mature to revenue-generation, and with big indication areas for Shire like ADHD at risk from generic and branded competition, the pressure is on the new CEO – even before he officially starts work.
Plus recent news on Amarin, Moderna Therapeutics, ArmaGen and Flexion
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Shire PLC
- Senior Management
Dirk Reyn, CEO
Catherine Moukheibir, CFO
Lieve Vandeplassche, PhD, Chief Dev. Officer
Jan Schuurkes, PhD, CSO
Bertrand Verwee, VP, Mktg.
- Contact Info
Phone: (32) 14 404 390
Veedijk 58 (1004)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.